References
Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:460–465.
Sato A, Saruta T: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients. J Int Med Res 2001, 29:13–21.
Wambach G, Helber A, Bonner G, et al.: Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn’s syndrome. Deutsch Med Wochenschr 1980, 105:647–651.
Karlberg BE, Kagedal B, Tegler L, Kerstin T: Renin concentrations and effects of propranolol and spironolactone in patients with hypertension. BMJ 1976, 1:251–254.
Lim PO, Jung RT, MacDonald TM: Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002, 16:153–158.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.
The RALES Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.
Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110:438–441.
Barzilay JI, Jones CL, Davis BR, et al.: Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001, 24:654–658.
Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.
McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723.
McFarlane SI, Farag A, Sowers J: Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003, 21:105–118.
The SOLVD Investigators: Effects of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992, 327:685–691.
Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.
Rights and permissions
About this article
Cite this article
Berecek, K.H., Farag, A., Bahtiyar, G. et al. Clinical trials report. Current Science Inc 6, 211–214 (2004). https://doi.org/10.1007/s11906-004-0071-z
Issue Date:
DOI: https://doi.org/10.1007/s11906-004-0071-z